Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trastuzumab-induced cardiotoxicity: is it a personalized risk?

Current drug targets - 1 Jan 2014

Milano Gerard A, Serres Emilie, Ferrero Jean-Marc, Ciccolini Joseph

Abstract excerpt

Optimal identification of the risk of developing cardiotoxicity upon trastuzumab (TZM) treatment appears necessary as this risk may impair treatment compliance and compromise long-term recovery. To better understand and predict cardiac toxicity, the molecular mechanisms underlying this phenomenon need to be known. HER2 is present at the cell surface of cardiomyocytes. Neuregulin is produced by cardiac endothelial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents
Share to Heart Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myocytes, Cardiac

Share to Precision Medicine

Share to Receptor, ErbB-2

Share to Receptor, ErbB-4

Share to Trastuzumab

Source

Identifiers

PMID: 25395105
DOI: 10.2174/1389450115666141114151911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trastuzumab-induced cardiotoxicity: is it a personalized risk?PMID 25395105Read ↗

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.Semantic proximity Read ↗

A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese PopulationSemantic proximity Read ↗

Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer without Risk Factors of Cardiotoxicity. Possibility of Omitting Cardiac Monitoring during Treatment.Semantic proximity Read ↗

Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.Semantic proximity Read ↗

Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity Read ↗

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Semantic proximity Read ↗

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trialSemantic proximity Read ↗

Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.Semantic proximity Read ↗

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer.Semantic proximity Read ↗

Genetic predisposition in chemotherapy-induced cardiomyopathy in a 65-year-old female with metastatic breast cancer.Semantic proximity Read ↗

Exploring the mechanism of action of trastuzumab-induced cardiomyocyte atrophy based on the FN1/PI3K/AKT-mediated mTOR-independent signaling pathwaySemantic proximity Read ↗

HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.